Singapore, Nov. 14 -- Agilent Technologies Inc. has announced the signing of a five-year Memorandum of Understanding (MoU) with National Heart Centre Singapore (NHCS) to accelerate innovation in metabolic heart failure research, one of the most complex and underserved areas in cardiovascular medicine.

Heart failure remains a leading global cause of death and disability, with metabolic forms such as diabetic heart failure and heart failure with preserved ejection fraction (HFpEF) posing challenges due to limited treatment options.

Under this agreement, Agilent and NHCS will combine their expertise in human cardiac organoids using human-derived heart tissues with cutting-edge analytical technologies, including Agilent's latest Seahorse XF...